Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-Current Deffered Revenue (2020 - 2025)

Candel Therapeutics' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $108000.0 for Q3 2023.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $108000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $108000.0, a N/A change, with the full-year FY2022 number at $144000.0, down 83.89% from a year prior.
  • Non-Current Deffered Revenue hit $108000.0 in Q3 2023 for Candel Therapeutics, down from $120000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for CADL hit a ceiling of $894000.0 in Q4 2021 and a floor of $31000.0 in Q3 2021.
  • Historically, Non-Current Deffered Revenue has averaged $266875.0 across 4 years, with a median of $128500.0 in 2020.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 615.2% in 2021 and later plummeted 83.89% in 2022.
  • Tracing CADL's Non-Current Deffered Revenue over 4 years: stood at $125000.0 in 2020, then surged by 615.2% to $894000.0 in 2021, then plummeted by 83.89% to $144000.0 in 2022, then fell by 25.0% to $108000.0 in 2023.
  • Business Quant data shows Non-Current Deffered Revenue for CADL at $108000.0 in Q3 2023, $120000.0 in Q2 2023, and $132000.0 in Q1 2023.